SPOTLIGHT -
Health Plan Saved by Switching from Cosentyx to Taltz
A proof-of-concept study showed that patients can be successfully switched from Cosentyx to Taltz with similar outcomes and lower costs.
AMCP 2022: Patients with Rare Liver Disease Need Treatment Adherence Support
AllianceRx Walgreens Prime study has found that patients taking Ocaliva may not be adherent to their treatment regimen for rare liver disease.
AMCP 2022: Payers Skeptical of Patient Input in Formulary Process
A disconnect exists between payers and patients with rare diseases about including patient input in the formulary process for orphan drugs.
Survey: Biosimilars are Gaining Momentum Among Payers
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Survey: Payers are Creating New Reimbursement Solutions for Gene Therapies
Most of the solutions have established systems to track patient outcomes over time, and several include performance guarantees as part of their solution.